Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.
Stocks · News reference
BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415
BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Market Perform and lowers the price target from $450 to $415.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $430
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $435 to $430.
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
Johnson & Johnson will report Q3 2026 results on October 13 with consensus estimates for $25.37 billion in sales and $2.66 EPS. The company's Innovative Medicine segment is expected to drive growth through key drugs like Darzalex and new launches, but faces headwinds from Stelara biosimilar competition and upcoming patent expirations. Despite valuation concerns, analysts recommend staying invested given J&J's diversified business model, consistent growth trajectory, and pipeline strength.